Literature DB >> 111876

Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis.

A C Lindsay-Miller.   

Abstract

A double-blind group comparative trial comparing Opticrom with a matching placebo, over a four-week period, in seasonal allergic conjunctivitis is reported. Overall assessment of treatment benefit made at the end of the trial by the patients and the clinician showed a statistically significant difference in favour of Opticrom. Of the patients on Opticrom, eighteen (90%) said they improved while in the clinicians opinion, seventeen (85%) improved. Six patients using Opticrom and five using placebo complained of stinging of the eyes, while one patient using placebo complained of his eyes becoming bloodshot and watering.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111876     DOI: 10.1111/j.1365-2222.1979.tb01553.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  5 in total

Review 1.  Conjunctival allergen challenge: models in the investigation of ocular allergy.

Authors:  Mark B Abelson; Oliver Loeffler
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

Review 2.  Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.

Authors:  E M Sorkin; A Ward
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 3.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 4.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 5.  Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness.

Authors:  Christopher G Owen; Anupa Shah; Katherine Henshaw; Liam Smeeth; Aziz Sheikh
Journal:  Br J Gen Pract       Date:  2004-06       Impact factor: 5.386

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.